{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:46:24Z","timestamp":1790009184609,"version":"4.0.1"},"reference-count":66,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,14]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>IRF4 deletion in Tcl-1 tg mice and IRF4low CLL patients enhances disease progression due to increased tumor immune evasion. This is caused by a downregulation of the antigen processing and presentation machinery and reduced T-cell costimulation.<\/jats:p>","DOI":"10.1182\/blood.2019000973","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T02:05:58Z","timestamp":1568945158000},"page":"1717-1729","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["B-cell\u2013specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion"],"prefix":"10.1182","volume":"134","author":[{"given":"Daniela","family":"Asslaber","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Maeding","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-6347","authenticated-orcid":false,"given":"Markus","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Denk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philip","family":"H\u00f6pner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-7179","authenticated-orcid":false,"given":"Tanja Nicole","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Zaborsky","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-4416","authenticated-orcid":false,"given":"Alexander","family":"Egle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria;"},{"name":"Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria; and"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,19]]},"reference":[{"issue":"1","key":"2019111602090655200_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"2019111602090655200_B2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111602090655200_B3","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Kr\u00f6ber","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111602090655200_B4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019111602090655200_B5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrclinonc.2009.72","article-title":"Molecular and cellular mechanisms of CLL: novel therapeutic approaches","volume":"6","author":"Pleyer","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2019111602090655200_B6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2796.2008.02030.x","article-title":"Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation","volume":"264","author":"Ghia","year":"2008","journal-title":"J Intern Med"},{"issue":"20","key":"2019111602090655200_B7","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2010-05-284505","article-title":"Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo","volume":"116","author":"Seiffert","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111602090655200_B8","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","article-title":"PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia","volume":"113","author":"Holler","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111602090655200_B9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2012.12.003","article-title":"Protein kinase c-\u03b2-dependent activation of NF-\u03baB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo","volume":"23","author":"Lutzny","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111602090655200_B10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CJI.0b013e318197b5e4","article-title":"Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease","volume":"32","author":"Tinhofer","year":"2009","journal-title":"J Immunother"},{"issue":"1","key":"2019111602090655200_B11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cytob.21120","article-title":"Distinctive patterns of na\u00efve\/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients","volume":"86","author":"Monserrat","year":"2014","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2019111602090655200_B12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.13467","article-title":"Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model","volume":"170","author":"Gassner","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111602090655200_B13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111602090655200_B14","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111602090655200_B15","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2011.111","article-title":"Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL","volume":"25","author":"Hofbauer","year":"2011","journal-title":"Leukemia"},{"issue":"15","key":"2019111602090655200_B16","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111602090655200_B17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111602090655200_B18","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2019111602090655200_B19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1007\/s12272-016-0854-1","article-title":"Essential role of interferon regulatory factor 4 (IRF4) in immune cell development","volume":"39","author":"Nam","year":"2016","journal-title":"Arch Pharm Res"},{"issue":"5","key":"2019111602090655200_B20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2013.10.007","article-title":"Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation","volume":"39","author":"Yao","year":"2013","journal-title":"Immunity"},{"issue":"7","key":"2019111602090655200_B21","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/eji.201344279","article-title":"IRF4 at the crossroads of effector T-cell fate decision","volume":"44","author":"Huber","year":"2014","journal-title":"Eur J Immunol"},{"issue":"37","key":"2019111602090655200_B22","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1073\/pnas.1309378110","article-title":"The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells","volume":"110","author":"Raczkowski","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"52","key":"2019111602090655200_B23","doi-asserted-by":"crossref","first-page":"20846","DOI":"10.1073\/pnas.0809077106","article-title":"IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype","volume":"105","author":"Huber","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"2019111602090655200_B24","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1073\/pnas.1205834109","article-title":"Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation","volume":"109","author":"Bollig","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111602090655200_B25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.1201443","article-title":"Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA","volume":"191","author":"Pan","year":"2013","journal-title":"J Immunol"},{"issue":"2","key":"2019111602090655200_B26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ni.2795","article-title":"Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation","volume":"15","author":"Vander Lugt","year":"2014","journal-title":"Nat Immunol"},{"issue":"10","key":"2019111602090655200_B27","doi-asserted-by":"crossref","first-page":"e25812","DOI":"10.1371\/journal.pone.0025812","article-title":"Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development","volume":"6","author":"Yamamoto","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"2019111602090655200_B28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1189\/jlb.1A0215-068RR","article-title":"Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function","volume":"100","author":"Nam","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2019111602090655200_B29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.imbio.2017.10.005","article-title":"The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2","volume":"223","author":"Chistiakov","year":"2018","journal-title":"Immunobiology"},{"issue":"5","key":"2019111602090655200_B30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/sji.12343","article-title":"IRF4 deficiency leads to altered BCR signalling revealed by enhanced PI3K pathway, decreased SHIP expression and defected cytoskeletal responses","volume":"82","author":"Budzy\u0144ska","year":"2015","journal-title":"Scand J Immunol"},{"issue":"1","key":"2019111602090655200_B31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-065X.2012.01113.x","article-title":"The diverse roles of IRF4 in late germinal center B-cell differentiation","volume":"247","author":"De Silva","year":"2012","journal-title":"Immunol Rev"},{"issue":"7","key":"2019111602090655200_B32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat Immunol"},{"issue":"5299","key":"2019111602090655200_B33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.275.5299.540","article-title":"Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function","volume":"275","author":"Mittr\u00fccker","year":"1997","journal-title":"Science"},{"issue":"6","key":"2019111602090655200_B34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"7201","key":"2019111602090655200_B35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"7","key":"2019111602090655200_B36","doi-asserted-by":"crossref","first-page":"e22628","DOI":"10.1371\/journal.pone.0022628","article-title":"IRF4 is a suppressor of c-Myc induced B cell leukemia","volume":"6","author":"Pathak","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"2019111602090655200_B37","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood-2007-10-117838","article-title":"IRF-4 functions as a tumor suppressor in early B-cell development","volume":"112","author":"Acquaviva","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111602090655200_B38","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1093\/nar\/gki1001","article-title":"Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region","volume":"33","author":"Ortmann","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2019111602090655200_B39","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/ng.219","article-title":"A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia","volume":"40","author":"Di Bernardo","year":"2008","journal-title":"Nat Genet"},{"issue":"9","key":"2019111602090655200_B40","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/hmg\/ddq044","article-title":"Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus","volume":"19","author":"Crowther-Swanepoel","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2019111602090655200_B41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2141.2010.08270.x","article-title":"Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk","volume":"150","author":"Crowther-Swanepoel","year":"2010","journal-title":"Br J Haematol"},{"issue":"7574","key":"2019111602090655200_B42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"issue":"4","key":"2019111602090655200_B43","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-018-0260-4","article-title":"Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development","volume":"33","author":"Zaborsky","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2019111602090655200_B44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.12151","article-title":"Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?","volume":"160","author":"Asslaber","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111602090655200_B45","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1158\/1078-0432.CCR-18-1548","article-title":"BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-kappaB nuclear translocation","volume":"25","author":"Asslaber","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111602090655200_B46","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2012-03-416461","article-title":"Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression","volume":"120","author":"Chuang","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111602090655200_B47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111602090655200_B48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMp048184","article-title":"Predicting progression--ZAP-70 in CLL","volume":"351","author":"Hamblin","year":"2004","journal-title":"N Engl J Med"},{"issue":"37","key":"2019111602090655200_B49","doi-asserted-by":"crossref","first-page":"26430","DOI":"10.1074\/jbc.M113.475913","article-title":"Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4","volume":"288","author":"Ma","year":"2013","journal-title":"J Biol Chem"},{"issue":"16","key":"2019111602090655200_B50","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2013-03-492769","article-title":"A role for IRF4 in the development of CLL","volume":"122","author":"Shukla","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111602090655200_B51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition [published correction appears in Nat Rev Immunol. 2013;13(7):542]","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2019111602090655200_B52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk Res"},{"issue":"2","key":"2019111602090655200_B53","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ng1097-226","article-title":"Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma","volume":"17","author":"Iida","year":"1997","journal-title":"Nat Genet"},{"issue":"3","key":"2019111602090655200_B54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","article-title":"Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma","volume":"204","author":"Lenz","year":"2007","journal-title":"J Exp Med"},{"issue":"36","key":"2019111602090655200_B55","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111602090655200_B56","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.immuni.2017.11.003","article-title":"Ablation of transcription factor IRF4 promotes transplant acceptance by driving allogenic CD4+ T cell dysfunction","volume":"47","author":"Wu","year":"2017","journal-title":"Immunity"},{"issue":"7","key":"2019111602090655200_B57","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/cdd.2014.19","article-title":"IRF4 and BATF are critical for CD8+ T-cell function following infection with LCMV","volume":"21","author":"Grusdat","year":"2014","journal-title":"Cell Death Differ"},{"issue":"1","key":"2019111602090655200_B58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2249.2001.01617.x","article-title":"Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate","volume":"126","author":"Goddard","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2019111602090655200_B59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2002-03-0746","article-title":"Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia","volume":"101","author":"Rezvany","year":"2003","journal-title":"Blood"},{"key":"2019111602090655200_B60","first-page":"147","article-title":"Expression of MHC II genes","volume":"290","author":"Drozina","year":"2005","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"2019111602090655200_B61","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2004-03-0790","article-title":"E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII)","volume":"104","author":"van der Stoep","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111602090655200_B62","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"1","key":"2019111602090655200_B63","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"2019111602090655200_B64","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"issue":"13","key":"2019111602090655200_B65","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111602090655200_B66","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/20\/1717\/1506105\/bloodbld2019000973.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/20\/1717\/1506105\/bloodbld2019000973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T19:54:52Z","timestamp":1721764492000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/20\/1717\/374993\/Bcellspecific-IRF4-deletion-accelerates-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":66,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2019,9,19]]},"published-print":{"date-parts":[[2019,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000973","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,19]]}}}